Mereo BioPharma Group plc
http://mereobiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mereo BioPharma Group plc
Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
UK Firms Big And Small Benefit From Biotech Bubble
Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.
Mereo Licenses Setrusumab To Ultragenyx For Osteogenesis Imperfecta
Ultragenyx hopes to expand its bone disease franchise in a deal that frees up Mereo to focus on its anti-TIGIT immuno-oncology pipeline asset.
ESMO: Merck & Co Vibostolimab Data Are Another Validation Of TIGIT
A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Mereo BioPharma Group Ltd.
- Mereo BioPharma Group plc (MPH:LN)
- OncoMed Pharmaceuticals, Inc. (OMED)